Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gloria Ong

Internal Medicine Goodyear, AZ Medical Doctor

NPI 1134570971 CMS profile 6157607

1325 N Litchfield Rd Ste 110, Goodyear, AZ 85395

Open in the dashboard

General payments

$6,116

390 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gloria Ong of Goodyear, AZ is reported in the CMS Open Payments database as having received $6,116 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $432 21
2024 General $1,030 47
2023 General $633 34
2022 General $1,128 82
2021 General $1,315 92
2020 General $1,297 103
2019 General $281 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gloria Ong
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gloria Ong were reported at $432. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gloria Ong Internal Medicine median Middle half National median
2019 $281 $159 $48–$570 $163
2020 $1,297 $119 $33–$402 $114
2021 $1,315 $135 $37–$521 $132
2022 $1,128 $141 $42–$496 $149
2023 $633 $149 $45–$519 $160
2024 $1,030 $154 $47–$537 $164
2025 $432 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,177 101 payments
  2. GlaxoSmithKline, LLC. $824 82 payments
  3. AstraZeneca Pharmaceuticals LP $450 29 payments
  4. Pfizer Inc. $447 25 payments
  5. Abbott Laboratories $405 17 payments
  6. Janssen Pharmaceuticals, Inc $307 12 payments
  7. Astellas Pharma US Inc $288 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $274 14 payments
  9. AbbVie, Inc. $243 13 payments
  10. Sanofi-Aventis U.S. LLC $201 11 payments
  11. Other $1,502 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,116 390 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,040 89 payments
  2. RYBELSUS $886 75 payments
  3. TRELEGY ELLIPTA $575 57 payments
  4. ELIQUIS $293 17 payments
  5. ANORO ELLIPTA $207 22 payments
  6. XARELTO $187 11 payments
  7. FARXIGA $181 9 payments
  8. FreeStyle Libre 2 $179 7 payments
  9. SYMBICORT $173 10 payments
  10. INVOKANA $171 4 payments
  11. Other $4,377 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

4,065

Median for Internal Medicine: 777

Drug cost

$394,280

Median for Internal Medicine: $73,373

Branded share of claims

19.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 95 $122,698
Mounjaro Tirzepatide Brand 42 $51,977
Eliquis Apixaban Brand 31 $35,845
Farxiga Dapagliflozin Propanediol Brand 24 $30,271
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $27,300
Trulicity Dulaglutide Brand 17 $25,751
Jardiance Empagliflozin Brand 18 $24,849
Myrbetriq Mirabegron Brand 16 $20,408
Symbicort Budesonide/Formoterol Fumarate Brand 14 $3,809
Albuterol Sulfate Hfa Albuterol Sulfate Brand 103 $3,307

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$160,786

Of which drugs: $3,055

Medicare patients

510

Average age 75

Services billed

2,175

300 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 40%
Chronic kidney disease 37%
Diabetes 36%
Heart failure 29%
Atrial fibrillation 29%
Depression 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 23 23 $1,865

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $99
$99 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $82
$82 23 —
NURTEC ODT
  • PFIZER INC. $46
$46 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $40
$40 — —
ELIQUIS
  • PFIZER INC. $37
$37 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record